BREVITY: Brentuximab vedotin in patients with Hodgkin lymphoma
Research type
Research Study
Full title
BREVITY: A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
IRAS ID
109578
Contact name
Kathryn Paterson
Contact email
Eudract number
2012-000214-11
Clinicaltrials.gov Identifier
HO2002, CAS Number
Duration of Study in the UK
6 years, 0 months, 0 days
Research summary
The aim of BREVITY is to assess the effectiveness of a new drug called brentuximab vedotin in patients with newly diagnosed Hodgkin’s Lymphoma for whom standard chemotherapy is not considered a good option due to age or frailty. Brentuximab vedotin is a new type of drug known as an antibody-drug conjugate and is made up of 2 parts linked together, an anti-body and a chemotherapy drug. The antibody acts like a homing device, and takes the chemotherapy drug directly to the lymphoma cells, where it causes them to die when they try to divide. 30 Patients will be recruited from hospitals across the UK and will receive a maximum of 16 doses over 48 weeks.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
13/EM/0159
Date of REC Opinion
18 Jun 2013
REC opinion
Further Information Favourable Opinion